Product liability cases aimed at opioids have featured inflated damages and abatement costs, and responsibility for those costs has fallen on recognizable targets rather than true causal factors. Most opioid cases have ended in settlements, but such endings offer little in the way of closure to a problem that overwhelmed regulators and befuddled the entire medical profession. Courts were left to pick up the pieces, but the tools and data they were provided were woefully incomplete, with cl...